Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.58
NPSP's Cash to Debt is ranked higher than
58% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. NPSP: 1.58 )
NPSP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 96771
Current: 1.58

0.22
96771
Equity to Asset 0.46
NPSP's Equity to Asset is ranked higher than
61% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NPSP: 0.46 )
NPSP' s 10-Year Equity to Asset Range
Min: -1.62   Max: 0.99
Current: 0.46

-1.62
0.99
F-Score: 4
Z-Score: 11.97
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 6.98
NPSP's Operating margin (%) is ranked higher than
87% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. NPSP: 6.98 )
NPSP' s 10-Year Operating margin (%) Range
Min: -4401.9   Max: 47.29
Current: 6.98

-4401.9
47.29
Net-margin (%) 0.49
NPSP's Net-margin (%) is ranked higher than
83% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. NPSP: 0.49 )
NPSP' s 10-Year Net-margin (%) Range
Min: -4031.2   Max: 30.05
Current: 0.49

-4031.2
30.05
ROE (%) 0.92
NPSP's ROE (%) is ranked higher than
86% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. NPSP: 0.92 )
NPSP' s 10-Year ROE (%) Range
Min: -336.52   Max: 15.8
Current: 0.92

-336.52
15.8
ROA (%) 0.37
NPSP's ROA (%) is ranked higher than
86% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. NPSP: 0.37 )
NPSP' s 10-Year ROA (%) Range
Min: -63.13   Max: 14.73
Current: 0.37

-63.13
14.73
ROC (Joel Greenblatt) (%) 29.69
NPSP's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. NPSP: 29.69 )
NPSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3684.06   Max: 273.86
Current: 29.69

-3684.06
273.86
Revenue Growth (3Y)(%) 1.30
NPSP's Revenue Growth (3Y)(%) is ranked higher than
79% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NPSP: 1.30 )
NPSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -47.8   Max: 90.4
Current: 1.3

-47.8
90.4
EBITDA Growth (3Y)(%) -65.80
NPSP's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NPSP: -65.80 )
NPSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.6   Max: 87.7
Current: -65.8

-75.6
87.7
EPS Growth (3Y)(%) -36.20
NPSP's EPS Growth (3Y)(%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NPSP: -36.20 )
NPSP' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.9   Max: 278
Current: -36.2

-86.9
278
» NPSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NPSP Guru Trades in Q4 2013

Steven Cohen 123,245 sh (+16.38%)
RS Investment Management 1,536,945 sh (+6.75%)
Pioneer Investments 369,214 sh (-17.74%)
Columbia Wanger 3,635,300 sh (-18.22%)
» More
Q1 2014

NPSP Guru Trades in Q1 2014

John Burbank 6,756 sh (New)
Jim Simons 23,500 sh (New)
Mariko Gordon 14,828 sh (New)
Steven Cohen 260,800 sh (+111.61%)
RS Investment Management 1,529,445 sh (-0.49%)
Columbia Wanger 2,771,000 sh (-23.78%)
Pioneer Investments 274,256 sh (-25.72%)
» More
Q2 2014

NPSP Guru Trades in Q2 2014

Joel Greenblatt 12,104 sh (New)
Louis Moore Bacon 25,000 sh (New)
Eric Mindich 408,141 sh (New)
Mariko Gordon 15,986 sh (+7.81%)
Louis Moore Bacon 30,000 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
RS Investment Management Sold Out
Pioneer Investments 253,897 sh (-7.42%)
Columbia Wanger 1,736,720 sh (-37.33%)
» More
Q3 2014

NPSP Guru Trades in Q3 2014

Paul Tudor Jones 8,388 sh (New)
Pioneer Investments 296,370 sh (+16.73%)
Mariko Gordon 16,864 sh (+5.49%)
Joel Greenblatt Sold Out
Eric Mindich Sold Out
Louis Moore Bacon Sold Out
Columbia Wanger 1,257,320 sh (-27.6%)
» More
» Details

Insider Trades

Latest Guru Trades with NPSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$25.77 - $33.42 $ 36.0426%0
John Burbank 2014-06-30 Sold Out 0.01%$23.38 - $35.37 $ 36.0425%0
Joel Greenblatt 2014-06-30 New Buy0.01%$23.38 - $35.37 $ 36.0425%12104
Mariko Gordon 2014-03-31 New Buy0.02%$27.55 - $39.06 $ 36.045%14828
John Burbank 2014-03-31 New Buy0.01%$27.55 - $39.06 $ 36.045%6756
George Soros 2011-12-31 Sold Out 0.06%$4.97 - $7.76 $ 36.04482%0
George Soros 2011-09-30 Add 98.31%0.03%$6.11 - $10.18 $ 36.04350%545349
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2402.70
NPSP's P/E(ttm) is ranked higher than
87% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 2402.70 )
NPSP' s 10-Year P/E(ttm) Range
Min: 8.92   Max: 2402.67
Current: 2402.7

8.92
2402.67
P/B 29.30
NPSP's P/B is ranked higher than
59% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. NPSP: 29.30 )
NPSP' s 10-Year P/B Range
Min: 9.18   Max: 38.66
Current: 29.3

9.18
38.66
P/S 18.02
NPSP's P/S is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. NPSP: 18.02 )
NPSP' s 10-Year P/S Range
Min: 1.6   Max: 136.3
Current: 18.02

1.6
136.3
EV-to-EBIT 256.30
NPSP's EV-to-EBIT is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 256.30 )
NPSP' s 10-Year EV-to-EBIT Range
Min: -2633.6   Max: 38665.5
Current: 256.3

-2633.6
38665.5
Current Ratio 5.89
NPSP's Current Ratio is ranked higher than
78% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. NPSP: 5.89 )
NPSP' s 10-Year Current Ratio Range
Min: 0.52   Max: 96.48
Current: 5.89

0.52
96.48
Quick Ratio 5.10
NPSP's Quick Ratio is ranked higher than
76% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NPSP: 5.10 )
NPSP' s 10-Year Quick Ratio Range
Min: 0.52   Max: 96.48
Current: 5.1

0.52
96.48

Valuation & Return

vs
industry
vs
history
Price/Net Cash 212.00
NPSP's Price/Net Cash is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. NPSP: 212.00 )
NPSP' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 2993
Current: 212

1.76
2993
Price/Net Current Asset Value 61.08
NPSP's Price/Net Current Asset Value is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. NPSP: 61.08 )
NPSP' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 262.5
Current: 61.08

1.76
262.5
Price/Tangible Book 37.16
NPSP's Price/Tangible Book is ranked higher than
63% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. NPSP: 37.16 )
NPSP' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 52.15
Current: 37.16

1.6
52.15
Price/Median PS Value 2.96
NPSP's Price/Median PS Value is ranked higher than
72% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. NPSP: 2.96 )
NPSP' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 64.42
Current: 2.96

0.31
64.42
Price/Graham Number 78.35
NPSP's Price/Graham Number is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NPSP: 78.35 )
NPSP' s 10-Year Price/Graham Number Range
Min: 1.33   Max: 58.76
Current: 78.35

1.33
58.76
Earnings Yield (Greenblatt) 0.40
NPSP's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. NPSP: 0.40 )
NPSP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 22.1
Current: 0.4

0.1
22.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPM.Germany,
NPS Pharmaceuticals Inc was incorporated in Utah in 1986 and reincorporated in Delaware in 1992. The Company is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or disease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara is the Company's recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. 'NPS, 'NPS Pharmaceuticals', 'GATTEX', and 'PREOS' are the Company's trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK